97 related articles for article (PubMed ID: 8764587)
21. Flesinoxan dose-dependently reduces extracellular 5-hydroxytryptamine (5-HT) in rat median raphe and dorsal hippocampus through activation of 5-HT1A receptors.
Bosker FJ; de Winter TY; Klompmakers AA; Westenberg HG
J Neurochem; 1996 Jun; 66(6):2546-55. PubMed ID: 8632181
[TBL] [Abstract][Full Text] [Related]
22. Serotonin 5-HT1D and 5-HT1A receptors respectively mediate inhibition of glutamate release and inhibition of cyclic GMP production in rat cerebellum in vitro.
Maura G; Raiteri M
J Neurochem; 1996 Jan; 66(1):203-9. PubMed ID: 8522955
[TBL] [Abstract][Full Text] [Related]
23. Hippocampal 8-[3H]hydroxy-2-(di-n-propylamino) tetralin binding site densities, serotonin receptor (5-HT1A) messenger ribonucleic acid abundance, and serotonin levels parallel the activity of the hypothalamopituitary-adrenal axis in rat.
Burnet PW; Mefford IN; Smith CC; Gold PW; Sternberg EM
J Neurochem; 1992 Sep; 59(3):1062-70. PubMed ID: 1379629
[TBL] [Abstract][Full Text] [Related]
24. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
[TBL] [Abstract][Full Text] [Related]
25. Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study.
Hjorth S
J Neurochem; 1993 Feb; 60(2):776-9. PubMed ID: 8419553
[TBL] [Abstract][Full Text] [Related]
26. Neurochemical profile of the selective and silent 5-HT1A receptor antagonist WAY100135: an in vivo microdialysis study.
Routledge C; Gurling J; Wright IK; Dourish CT
Eur J Pharmacol; 1993 Aug; 239(1-3):195-202. PubMed ID: 8223894
[TBL] [Abstract][Full Text] [Related]
27. Single exposure to a serotonin 1A receptor agonist, (+)8-hydroxy-2-(di-n-propylamino)-tetralin, produces a prolonged heterologous desensitization of serotonin 2A receptors in neuroendocrine neurons in vivo.
Carrasco GA; Van de Kar LD; Jia C; Xu H; Chen Z; Chadda R; Garcia F; Muma NA; Battaglia G
J Pharmacol Exp Ther; 2007 Mar; 320(3):1078-86. PubMed ID: 17159160
[TBL] [Abstract][Full Text] [Related]
28. Extracellular serotonin and 5-hydroxyindoleacetic acid in hypothalamus of the unanesthetized rat measured by in vivo dialysis coupled to high-performance liquid chromatography with electrochemical detection: dialysate serotonin reflects neuronal release.
Auerbach SB; Minzenberg MJ; Wilkinson LO
Brain Res; 1989 Oct; 499(2):281-90. PubMed ID: 2478259
[TBL] [Abstract][Full Text] [Related]
29. Short-term exposure to constant light promotes strong circadian phase-resetting responses to nonphotic stimuli in Syrian hamsters.
Knoch ME; Gobes SM; Pavlovska I; Su C; Mistlberger RE; Glass JD
Eur J Neurosci; 2004 May; 19(10):2779-90. PubMed ID: 15147311
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.
Kleven MS; Assié MB; Koek W
J Pharmacol Exp Ther; 1997 Aug; 282(2):747-59. PubMed ID: 9262338
[TBL] [Abstract][Full Text] [Related]
31. 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine.
Assié MB; Cosi C; Koek W
Eur J Pharmacol; 1997 Sep; 334(2-3):141-7. PubMed ID: 9369342
[TBL] [Abstract][Full Text] [Related]
32. Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex by (R)- and (S)-zacopride.
Barnes NM; Cheng CH; Costall B; Ge J; Naylor RJ
Br J Pharmacol; 1992 Sep; 107(1):233-9. PubMed ID: 1384906
[TBL] [Abstract][Full Text] [Related]
33. Destruction of the nucleus raphe obscurus and potentiation of serotonin-mediated behaviors following administration of the neurotoxin 3-acetylpyridine.
Wieland S; Kreider MS; McGonigle P; Lucki I
Brain Res; 1990 Jun; 520(1-2):291-302. PubMed ID: 1698505
[TBL] [Abstract][Full Text] [Related]
34. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors.
Delgado M; Caicoya AG; Greciano V; Benhamú B; López-Rodríguez ML; Fernández-Alfonso MS; Pozo MA; Manzanares J; Fuentes JA
Eur J Pharmacol; 2005 Mar; 511(1):9-19. PubMed ID: 15777774
[TBL] [Abstract][Full Text] [Related]
35. Endogenous release of neuronal serotonin and 5-hydroxyindoleacetic acid in the caudate-putamen of the rat as revealed by intracerebral dialysis coupled to high-performance liquid chromatography with fluorimetric detection.
Kalén P; Strecker RE; Rosengren E; Björklund A
J Neurochem; 1988 Nov; 51(5):1422-35. PubMed ID: 2459309
[TBL] [Abstract][Full Text] [Related]
36. Nucleus accumbens serotonin1A receptors control cocaine-induced hyperactivity but not local serotonin increase: an in vivo microdialysis study.
Müller CP; Thönnessen H; De Souza Silva MA; Fink H; Bert B; Carey RJ; Huston JP
Neuropharmacology; 2004 Aug; 47(2):205-15. PubMed ID: 15223299
[TBL] [Abstract][Full Text] [Related]
37. 8-OH-DPAT influences extracellular levels of serotonin and dopamine in the medial preoptic area of male rats.
Lorrain DS; Matuszewich L; Hull EM
Brain Res; 1998 Apr; 790(1-2):217-23. PubMed ID: 9593901
[TBL] [Abstract][Full Text] [Related]
38. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635.
Forster EA; Cliffe IA; Bill DJ; Dover GM; Jones D; Reilly Y; Fletcher A
Eur J Pharmacol; 1995 Jul; 281(1):81-8. PubMed ID: 8566121
[TBL] [Abstract][Full Text] [Related]
39. Pindolol suppresses serotonergic neuronal activity and does not block the inhibition of serotonergic neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats.
Fornal CA; Martin FJ; Metzler CW; Jacobs BL
J Pharmacol Exp Ther; 1999 Oct; 291(1):229-38. PubMed ID: 10490909
[TBL] [Abstract][Full Text] [Related]
40. Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties.
Assié MB; Koek W
Eur J Pharmacol; 1996 May; 304(1-3):15-21. PubMed ID: 8813579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
